Form 4: Tenaya Therapeutics Executive Receives Stock Options and Restricted Stock Units Following Option Repricing

A Form 4 filing reveals that Tenaya Therapeutics' Chief Medical Officer, Whittemore Tingley, received stock options and restricted stock units, and had existing options repriced, following a company-wide option repricing.

Summary

• Tenaya Therapeutics' Chief Medical Officer, Whittemore Tingley, received 40,000 restricted stock units that vest starting August 15, 2025, and 31,676 restricted stock units that vest starting May 15, 2025.
• Tingley also received 235,000 stock options that vest monthly starting February 24, 2025.
• Existing stock options held by Tingley with exercise prices above $3.00 were repriced to $1.21 per share, the closing price of the company's stock on January 24, 2025.
• The repriced options have a 'Retention Period' ending on July 24, 2025, or a change in control, during which exercising the options will incur a premium equal to the original exercise price.
• The option repricing affected all continuing employees and certain service providers with options having exercise prices of $3.00 or more.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and a common strategy of option repricing to retain employees. While the 'Retention Period' adds a layer of complexity, the overall sentiment is neutral to positive as it aims to align executive interests with the company's long-term success.

Positives

• The grant of restricted stock units and stock options to the Chief Medical Officer aligns his interests with the company's success.
• The option repricing provides an incentive for employees and service providers by lowering the exercise price of their options.
• The vesting schedules for the new grants and repriced options encourage long-term commitment from the executive.

Negatives

• The 'Retention Period' for the repriced options could be seen as a restriction on the executive's ability to benefit from the repricing immediately.
• The premium exercise price during the 'Retention Period' could be confusing or seen as a negative by some option holders.

Risks

• The 'Retention Period' could potentially disincentivize employees if they are considering leaving before July 24, 2025.
• The option repricing could be perceived negatively if the stock price does not increase significantly, as the original exercise prices may still be relevant during the retention period.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedules of the granted securities and the retention period for the repriced options.

Industry Context

Option repricing is a common practice in the biotech industry, especially when a company's stock price has declined. It is used to retain and motivate employees by making their stock options more valuable.

Comparison to Industry Standards

• Option repricing is a common practice in the biotech industry, particularly for companies that have experienced a decline in stock price.
• Many biotech companies use similar vesting schedules for stock options and restricted stock units, typically over a four-year period with monthly or semi-annual vesting.
• The 'Retention Period' is a less common feature, but it is used to ensure that employees remain with the company for a specific period after the repricing.

Stakeholder Impact

• Shareholders may view the option repricing as a positive step to retain talent and align employee interests with the company's performance.
• Employees with repriced options will benefit from the lower exercise price, but they must remain with the company during the 'Retention Period' to avoid paying a premium.
• The Chief Medical Officer benefits from the new grants and the repricing of existing options.

Next Steps

• The restricted stock units will vest according to their respective schedules.
• The new stock options will vest monthly starting February 24, 2025.
• The 'Retention Period' for the repriced options will end on July 24, 2025, or upon a change of control.

Key Dates

Keywords

stock options, restricted stock units, option repricing, executive compensation, Form 4, Tenaya Therapeutics, vesting, retention period